Roxadustat (Romanian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Roxadustat" in Romanian language version.

refsWebsite

Global rank Romanian rank

9nih.gov

4^th place

8doi.org

2^nd place

3^rd place

2europa.eu

68^th place

19^th place

1ebi.ac.uk

5,849^th place

138^th place

1cas.org

8,332^nd place

310^th place

1chemspider.com

8,573^rd place

247^th place

1astellas.us

low place

1wikidata.org

43^rd place

2^nd place

1anm.ro

low place

352^nd place

1pharmaceutical-technology.com

low place

7,372^nd place

1harvard.edu

18^th place

27^th place

anm.ro

nomenclator.anm.ro

Nomenclatorul medicamentelor pentru uz uman. ANMDMR (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

astellas.us

newsroom.astellas.us

„Astellas Receives Approval of Evrenzo (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis”. Astellas^⁠(d). 27 noiembrie 2020.

cas.org

commonchemistry.cas.org

CAS Common Chemistry, accesat în 8 aprilie 2021

chemspider.com

Roxadustat (în engleză), ChemSpider, accesat în 3 octombrie 2016

doi.org

„Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD”. Clinical Journal of the American Society of Nephrology. 11 (6): 982–91. iunie 2016. doi:10.2215/CJN.06890615. PMC 4891748 . PMID 27094610.
„A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat”. Advances in Therapy. 34 (4): 848–853. aprilie 2017. doi:10.1007/s12325-017-0508-9. PMID 28290095.
„Roxadustat: First Global Approval”. Drugs. 79 (5): 563–572. aprilie 2019. doi:10.1007/s40265-019-01077-1. PMID 30805897.
„The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model”. Scientific Reports. 9 (1): 6035. aprilie 2019. Bibcode:2019NatSR...9.6035Z. doi:10.1038/s41598-019-41924-5. PMC 6465281 . PMID 30988335.
„Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis”. The New England Journal of Medicine. 381 (11): 1001–1010. septembrie 2019. doi:10.1056/NEJMoa1813599. PMID 31340089.
„Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis”. Drug Testing and Analysis. 4 (11): 830–45. noiembrie 2012. doi:10.1002/dta.390. PMID 22362605.
„Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case”. Journal of Pharmaceutical and Biomedical Analysis. 121: 181–187. martie 2016. doi:10.1016/j.jpba.2016.01.029. PMID 26808067.
„lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls”. Drug Testing and Analysis. 9 (11–12): 1768–1778. noiembrie 2017. doi:10.1002/dta.2202. PMID 28378453.

ebi.ac.uk

roxadustat (în engleză), ChEBI, accesat în 3 octombrie 2016

europa.eu

ema.europa.eu

Evrenzo. Rezumatul caracteristicilor produsului și prospectul. Agenția Europeană pentru Medicamente (EMA)
„Evrenzo EPAR”. European Medicines Agency (EMA). 23 iunie 2021. Accesat în 24 august 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

harvard.edu

adsabs.harvard.edu

„The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model”. Scientific Reports. 9 (1): 6035. aprilie 2019. Bibcode:2019NatSR...9.6035Z. doi:10.1038/s41598-019-41924-5. PMC 6465281 . PMID 30988335.

nih.gov

ncbi.nlm.nih.gov

„Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD”. Clinical Journal of the American Society of Nephrology. 11 (6): 982–91. iunie 2016. doi:10.2215/CJN.06890615. PMC 4891748 . PMID 27094610.
„A New Approach to the Management of Anemia in CKD Patients: A Review on Roxadustat”. Advances in Therapy. 34 (4): 848–853. aprilie 2017. doi:10.1007/s12325-017-0508-9. PMID 28290095.
„Roxadustat: First Global Approval”. Drugs. 79 (5): 563–572. aprilie 2019. doi:10.1007/s40265-019-01077-1. PMID 30805897.
„The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model”. Scientific Reports. 9 (1): 6035. aprilie 2019. Bibcode:2019NatSR...9.6035Z. doi:10.1038/s41598-019-41924-5. PMC 6465281 . PMID 30988335.
„Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis”. The New England Journal of Medicine. 381 (11): 1001–1010. septembrie 2019. doi:10.1056/NEJMoa1813599. PMID 31340089.
„Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis”. Drug Testing and Analysis. 4 (11): 830–45. noiembrie 2012. doi:10.1002/dta.390. PMID 22362605.
„Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case”. Journal of Pharmaceutical and Biomedical Analysis. 121: 181–187. martie 2016. doi:10.1016/j.jpba.2016.01.029. PMID 26808067.
„lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls”. Drug Testing and Analysis. 9 (11–12): 1768–1778. noiembrie 2017. doi:10.1002/dta.2202. PMID 28378453.

pubchem.ncbi.nlm.nih.gov

„Roxadustat”, FG-4592 (în engleză), PubChem, accesat în 3 octombrie 2016

pharmaceutical-technology.com

„FDA declines to approve FibroGen's roxadustat for anaemia of CKD”. Pharmaceutical Technology. 12 august 2021.

wikidata.org

„Astellas Receives Approval of Evrenzo (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis”. Astellas^⁠(d). 27 noiembrie 2020.